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Conclusion: The alpha version of the tool is a first step 
towards its implementation in the clinical practice. The tool 
will be tested further by patients, to investigate whether it 
(a) influences the quality of the decision; (b) can be used 
without support. The tool is available in Dutch, English and 
Italian. Future efforts include the development of decision 
tools for other primary tumors. 
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Purpose or Objective: The increased use of magnetic 
resonance imaging (MRI) for radiotherapy (RT) target 
delineation has encouraged method development to enable 
the entire RT treatment planning workflow based on MRI 
only. Earlier we have presented a procedure for MRI only 
based treatment planning replacing planning CT in all phases 
of RT including simulation, target volume definition, dose 
calculation based on a pseudo-CT image set generated from 
MRI, and image guidance where comparison between MR or 
pseudo-CT reference set and MV/kV planar images or cone-
beam CT is performed. The method has been applied 
clinically for RT planning of localized prostate cancer since 
November, 2012. Here we present our early clinical 
experience. 
 
Material and Methods: We have followed n = 125 patients 
treated with MRI only procedure with serum prostate-specific 
antigen (PSA) at the beginning (baseline) and end of the RT 
course. As a reference, similar group of patients has been 
chosen where RT were planned with similar irradiation 
technique, margins, dosage (prostate 76 Gy in 2 Gy fractions, 
seminal vesicles 66 Gy in 2 Gy fractions) and image guidance 
method (gold seeds + daily kV/MV imaging), but where CT 
planning image set has been used as a primary data set in 
treatment planning and IGRT, and MRI images were 
registered to CT for target delineation. For the reference 
group, equal number of patients with additional antiandrogen 
therapy (n = 100) or RT only (n = 25) were chosen. 
 
Results: Mean PSA values for all the patient subgroups are 
presented in Table 1. The two methods show equal early 
response in PSA. No difference in early toxicity was noticed 
between the MRI only and CT+MRI groups. 
 
 
 
Conclusion: MRI only based RT treatment planning gave 
expected and equivalent results after RT compared with CT 
(MRI registered) based treatment planning procedure. Longer 
follow-up is needed to confirm the clinical equivalence 
related both to tumour response and normal tissue toxicity. 
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Purpose or Objective: On the basis of radiobiological studies 
suggesting a low α/β ratio for prostate adenocarcinoma, 
hypofractionation has been proposed to improve outcome in 
localized prostate cancer. STIP trial is a single center 
prospective phase I/II trial, with the aim of investigating 
feasibility and safety of moderate hypofractionation in low 
and intermediate risk (LR and IR) prostate cancer with Helical 
Tomotherapy (HT). We report early results in the first twelve 
recruited patients. 
 
Material and Methods: Inclusion criteria are: histologically 
confirmed adenocarcinoma, age ≥ 18  and ≤ 85 years, LR and 
IR according to NCCN, performance status (Karnofsky) ≥ 60, 
no clinical or radiological sign of metastasis, International 
Prostate Symptom Score (IPSS) ≤ 19, no previous cancer 
history.The addition of short-term Androgen Deprivation 
Therapy to radiation is prescribed for IR patients and 
performed for 6 months. CT/MR simulation and all treatment 
sessions were performed with empty rectum and comfortably 
full bladder. Clinical target volume (CTV) 1 comprised the 
prostate gland in 11 LR patients, CTV2 also included the 
seminal vesicles in one IR patient. Planning target volumes 
(PTV) 1 and 2 were defined, respectively, as CTV1 and 2 plus 
a 0.5 cm margin. Total doses of 60 Gy and 54 Gy were 
delivered, in 20 fractions, to PTV1 and 2, respectively. To 
compare CTVs and PTVs obtained with CT and MRI, these 
volumes were contoured on CT scans and then on the merged 
image sets. Before each fraction, daily megavoltage 
tomography (MCVT) was performed to reduce interfraction 
uncertainties. 
 
Results: Median follow-up was 12 months (range 3–20 
months). Mean dose to PTV1 was 60.15 Gy ( range 59.98-
60.27), mean dose to PTV2 was 54.65 Gy. According to CTCAE 
3.0 scale, acute G1 and G2 gastrointestinal toxicity occurred 
in 3 (25%) and 1 (8%) patients, respectively; no patients 
experienced G3 toxicity. G1 genitourinary toxicity occurred 
in 6 (50%) patients and no G2 or higher grade side effects 
were observed. According to the Expanded Prostate Cancer 
Index Composite (EPIC) questionnaire, urinary function 
declined 3 months post-treatment but it was similar to 
baseline at 12 months; bowel related quality of life remained 
stable during follow-up. IPSS remained similar to baseline for 
all patients. The contoured volume analysis showed that CTV 
and PTV based on MRI were always lower than CT based 
volumes (mean 38.07-87.10 vs 50.84-106). No patients 
experienced biochemical failure during follow-up. 
 
Conclusion: Our preliminary data support the safety of a 20-
fraction hypofractionated schedule delivered with HT in 
patients with localized prostate cancer. 
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Purpose or Objective: Carbon ion is characterized by unique 
physical and biological properties which is expected to be 
suitable to treat localized prostate cancer. In order to assess 
validate the feasibility and efficacy of carbon-ion 
radiotherapy for prostatic cancer, we synthesize and 
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compare available evidence of carbon ion therapy prostatic 
cancer by meta analysis. 
 
Material and Methods: PubMed,Embase,The Cochrane 
Library,Web of Science,the Chinese Biomedical Literature 
Database were systemically searched from 1980 to May 2015 
by heavy ion,carbon ion,carbon and 12C6+,to collect clinical 
study of carbon-ion radiotherapy for prostatic cancer.Two 
reviews independently screened citation extracted basic 
information of local control rate,overall survival rate and 
phase of clinical study,the related data were analyzed by 
Stata 12.0. 
 
Results: Three phase II clinical trials,four phase I/II clinical 
trials and one retrospective study were included,which 
included 1307 patients.the meta analysis showed 3-,4-,5-,and 
8-year overall survival rates were 
0.934(95%CI:0.901,0.968),0.909(95%CI:0.866,0.951),0.872(95
%CI:0.844,0.899) and 0.839(95%CI:0.793,0.884) and the 4-, 5-
year local control rate were 0.989(95%CI:0.973,1.004) and 
0.99(95%CI:0.969,1.01), respectively(Figure 1). 
 
 
Conclusion: Carbon ion therapy is suitable and tolerable for 
the treatment of prostate cancer, in the future,more 
evidence is required before carbon ion therapy can become 
internationally the standard treatment for prostate cancer 
patients. 
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Purpose or Objective: EORTC trial 22911 showed 75% 5-year 
biochemical disease-free survival (BDFS) in patients with 
prostate carcinoma (PCa) treated with radical prostatectomy 
(RP) followed by postoperative radiotherapy (RT). Aim of this 
study was to improve this outcomes by using a combined-
intensified-modulated-adjuvant (CIMA) treatment, based on 
RT and adjuvant hormone therapy (AHT). 
 
Material and Methods: The study hypothesis was that CIMA 
treatment may improve 5-year BDFS from 75% to 90%. The 
study was planned based on Simon’s phase II design. We 
needed to study 100 experimental subjects to be able to 
reject the null hypothesis that the success rates for standard 
and experimental treatments are equal with probability 
(power) 0.8. The Type I error probability associated with this 
test of this null hypothesis is 0.05. We used an uncorrected 
chi-squared statistic to evaluate this null hypothesis. Some 
over-recruitment was planned to allow for a continuous drop-
out process of up to 20% during the follow-up period. 
Enrolled patients were < 80 years old, with histological 
diagnosis of PCa, without known metastases, stage pT2-4 N0-
1, not previously treated and with ECOG performance status 
of 0-2. All patients had at least one of these pathologic 
features: capsular perforation, positive surgical margins, 
seminal vesicle invasion. Standard dose to the tumor bed was 
64.8 Gy. According to the pathological stage patients 
received a higher dose (70.2 Gy; 85.4%) and/or prophylactic 
irradiation of pelvic lymph nodes (57.7%) and/or adjuvant 
hormonal therapy (69.1%). 
 
Results: One-hundred-twenty-three patients were enrolled in 
the study and completed the planned CIMA treatment. 
Median preoperative and postoperative PSA were 8.8 and 
0.06 ng/dL, respectively. Proportion of patients with 
pathologically involved nodes and positive resection margin 
was 14.6 % and 58.5%, respectively. Median follow-up was 67 
months (interquartile range: 48.0-98.0 months). Actuarial 5-
year BDSF was 92.9%. Actuarial 5-year local control and 
metastasis-free survival were 99% and 96%, respectively. 
Actuarial 5-year overall survival was 95%. 
 
Conclusion: CIMA therapy, compared to studies based on 
standard adjuvant radiotherapy, resulted in an improved 5-
year BDFS, although patients with nodal metastatic disease 
and detectable postoperative PSA were enrolled in the study. 
A prolonged follow-up will be needed to confirm this 
improvement even in terms of disease-free survival and 
overall survival. 
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Purpose or Objective: Despite 3 large randomized studies on 
adjuvant radiotherapy (RT) proving a significantly improved 
biochemical recurrence free survival in patients (pts) with 
advanced prostate cancer (PCA), there is still an dispute 
regarding the need for adjuvant RT in those pts. The risk of 
recurrence in these advanced stages may reach 30% to 60%. 
Nevertheless many of those pts are not referred to adjuvant 
RT. We therefore performed a retrospective analysis of 94 
pts with pT3a pN0/cN0 R1-resected PCA in order to 
investigate the natural history of the disease and the benefit 
of adjuvant or salvage RT. 
 
Material and Methods: We included 94 pts with pT3a 
pN0/cN0 R1-resected PCA that had undergone prostatectomy 
no later than 2009. In 91 pts lymphadenectomy was 
performed with an average of 10 removed lymph nodes. 
Gleason-Score was mainly 7a in 33, 7b in 24 and 8 in 19 pts. 
Statistical analysis was performed using a Cox proportional 
hazard model and Kaplan Meier survival analysis. Median 
follow up was 80 months. 
 
Results: 71 pts had a PSA <0.07ng/ml after surgery. 35 of 
them experienced a biochemical relapse (Group 1). In 30 pts 
this occurred within the first 80 months. 28 of the pts with 
biochemical relapse received early salvage RT. PSA before 
salvage RT was in median 0.24ng/ml and after RT in 23 pts 
<0.07ng/ml. 36 pts were PSA negative after surgery and did 
not have any PSA relapse (Group 2). Nevertheless 14 of these 
pts received an additive RT treatment within the first 15 
months after surgery. At the last date of contact all 36 pts 
were still PSA negative. 23 pts were PSA positive after 
surgery (Group 3). 18 pts received an early salvage RT with a 
PSA in median of 0.4ng/ml (0.12-4.58). After RT PSA was 
0.28ng/ml (0.0-4.58). 5 pts in Group 1, 1 patient in Group 2 
and 9 pts in Group 3 received androgen deprivation therapy 
(ADT) after radiotherapy until the last date of contact. 
